Liver Cancer Molecular Diagnostics Market To 2025: Key Product Categories (Instruments, Reagents & Kits, Software & Services), Test Locations (Clinics, Point of Care), Key Technologies (PCR, In Situ Hybridization, Chips and microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass spectrometry, Sequencing, Transcription Mediated Amplification), Regional Segmentation, Pricing Analysis, Pipeline Analysis, Competitive Dynamics, M&A Insights, Segment Forecast and Conclusion

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global liver cancer molecular diagnostics market was valued at $115.3 Million in 2017 and is forecast to grow at a modest 13.7 % CAGR between 2018 and 2025, culminating in 2025 global sales of $355.2 Million.

 

Individualized and targeted treatments are reshaping oncology. Key to personalized medicine lies in molecular pathology. Use of high throughput sequencing technologies and identification of therapeutic targets has led to the development of many molecular diagnostic tests, which are far more superior to the conventional pathology tests. Despite recent development in novel targets and potential markers, the implementation of tests to identify in clinical and pathology practice is hard to achieve.

 

Global oncology molecular diagnostic market is expected to grow at a faster rate than expected due to rising demand from physicians, failure rate of conventional diagnosis, better and early detection, reducing cost of molecular diagnostic, improvement reimbursement coverage, technological, rising prevalence of chronic diseases and rapid increase in the geriatric population across the globe. Moreover, high unmet needs across the developing and emerging nations is also expected to boost the molecular diagnostics over the next few years.

 

Liver cancer is more prevalent in countries in sub-Saharan Africa and Southeast Asia than in the US. In many of these countries it is the most common type of cancer. More than 700,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. There are various types of primary liver cancer occur in adults. Some of the most common liver cancers include Hepatocellular carcinoma, Cholangiocarcinoma (bile duct cancer), and Angiosarcoma. These are named after the cells from which they developed. Among these, 80% of adult primary liver cancers are hepatocellular carcinomas, 10% to 20% of adult primary liver cancers are cholangiocarcinomas and only 1% of adult primary liver cancers are angiosarcomas. The outlook for liver cancer is poor, as it is often diagnosed at a late stage, at which point it has already spread to other organs or other parts of the liver. The survival rate reduces as the staging gets closer to Stage IV. People diagnosed at an early stage have a 5-year survival rate of 31%.

.

 

Aging factors significantly contribute to the onset of several oncological conditions. For instance, the average age for stomach cancer diagnosis is 69 and about every 6 in 10 patients diagnosed are aged above 65. The American Cancer Society estimates that nearly 28,000 stomach cancer cases will be diagnosed in 2017, with 17,750 cases in men and 10,250 cases in women. In the UK, as per 2014 Cancer Research estimates, each year nearly 6,682 new cases are detected, and the average survival rate is 15%.

.

 

Molecular Diagnostic Market 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Endoscope Equipment”

 

Estimated Average Oncology Molecular Diagnostics product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the molecular diagnostics products are available at USD 3600. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Product Insight

 

The oncology molecular diagnostics market is broadly segmented by product as Instruments, Reagents & Kits, Software & Services. Instruments like QIAsymphony SP/AS from QIAGEN and ELITe InGenius® from Elitech group are some of the instruments which integrate extraction, amplification and result interpretation with an unprecedented flexibility and assay menu possibility.

 

Reagents and kits are a large component of the overall market for Oncology Molecular Diagnostic. There are several options in the market for a wide range of usages from Thermo Fisher to Qiagen to Luminous Bioscience.

 

Today’s demanding business climate, rapid delivery of results from the lab directly to the patient has dramatically increased the informatics integration and workflow challenges in clinical testing and molecular diagnostic labs. Nautilus LIMS™ from Thermo Fisher is such a software solution.

 

Test Location Insights

 

Specialty clinics and laboratories constitute primary test locations for molecular diagnostic. Laboratories having high volume capacity are driving the market. However, to facilitate early diagnostic, POC (Pont of Care) diagnostic is increasing. Some of these POCs are retail clinics & pharmacies, student health clinics, neighborhood ambulatory care clinics, physician offices, CLIA waived labs, CLIA moderately complex labs, hospital floor (near-patient bedside), emergency rooms, intensive care units, rural health clinics, nursing homes, assisted living residence. CLIA waived labs are 5% of total POC and used primarily for respiratory testing.

 

Technology Insights

 

The oncology molecular diagnostics market is broadly segmented by technology as PCR, In Situ Hybridization, Chips and microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass spectrometry, Sequencing, Transcription Mediated Amplification. In 2017, PCR technology market share was little above 30% of market share. DNA and RNA sequencing expected to grow at a CAGR of 18% during the forecasted period and will provide high throughput analysis.

 

Regional Segmentation

 

North America accounted for over 46% revenue share in 2016. The key reasons attributed for the high share include the high prevalence of stomach and GI cancers, strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on preventive screening is expected to boost the usage rates over the forecast period.

 

Asia Pacific is expected to register the maximum CAGR of 7.5% through 2017 to 2025. The rapid increase in a number of cancer cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.

 

Merger and Acquisition Insight

 

With the rising investor confidence and positive market trends, several players are actively engaging in merger and acquisition activities. Moreover, the disruption in the global healthcare market due to political factors such as repealing Obama Care Act, changes in the regulatory framework, and other trade barriers, are anticipated to trigger merger and acquisition activities to drive market consolidation and further intensify the market competition. We have identified 4 major deals from 2014 to 2017.

 

Top Players & Company Share

 

The Oncology Molecular Diagnostic market is highly competitive and some of the key success factors include technology, pricing, and distribution channel. As of 2017, major players in the market include Cepheid, Beckton Dickinson, Gen Probe (Hologic), Qiagen, Roche Diagnostics, Bayer Healthcare, Dako, Abbott Laboratories, Danaher Corporation, Siemens, Sysmex Corporation, Grifols, and Biomérieux Sa.

 

Market Segmentation

 

Liver Cancer Molecular Diagnostics Market by Products (Revenue, USD Million, 2014 – 2025)

  • Instruments
  • Reagents & Kits
  • Software & Services

 

Liver Cancer Molecular Diagnostics Market by Test Location (Revenue, USD Million, 2014- 2025)

  • Clinics/Lab
  • Point of Care

 

Liver Cancer Molecular Diagnostics Market by Technology (Revenue, USD Million, 2014- 2025)

  • PCR
  • In Situ Hybridization
  • Chips and microarrays
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Mass spectrometry
  • Sequencing
  • Transcription Mediated Amplification

 

Liver Cancer Molecular Diagnostics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Liver Cancer Molecular Diagnostics Market Overview

  • Disease Landscape
  • Healthcare Expenditure

Chapter 4 Liver Cancer Molecular Diagnostics Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Major Buying Authorities and Decision-Making Process
  • Key Market Drivers
    • Rising demand from physicians
    • Failure rate of conventional diagnosis
    • Better and early detection
    • Improvement reimbursement coverage
    • Rising prevalence of chronic diseases
    • Rapid increase in the geriatric population
  • Key Market Challenges
    • High Cost of Molecular Diagnostic
    • Shortage of Trained Professionals
    • Accessibility of Diagnostic
  • Key Opportunities Prioritized
  • Company Market Share/Heat Map Analysis
  • Industry Analysis - Porter’s
  • Liver Cancer Molecular Diagnostics Market-PESTEL Analysis

Chapter 5: - Liver Cancer Molecular Diagnostics Market by “Product Type” (USD Million)

  • Liver Cancer Molecular Diagnostics Market Landscape by Product Type- 2014 & 2025
  • Instruments
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Reagents & Kits
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Software & Services
  • Market Landscape Analysis, 2014-2025 (USD Mn)
 

Chapter 6: - Liver Cancer Molecular Diagnostics Market by “Test Location” (USD Million)

  • Liver Cancer Molecular Diagnostics Market Landscape by Disease Type- 2014 & 2025
  • Clinics/Lab
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Point of Care (POC)
  • Market Landscape Analysis, 2014-2025 (USD Mn)
 

Chapter 7: - Liver Cancer Molecular Diagnostics Market by “Technology Type” (USD Million)

  • Liver Cancer Molecular Diagnostics Market Landscape by Treatment Type- 2014 & 2025
  • PCR
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • In Situ Hybridization
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Chips and microarrays
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Mass spectrometry
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Sequencing
  • Market Landscape Analysis, 2014-2025 (USD Mn)
  • Transcription Mediated Amplification
  • Market Landscape Analysis, 2014-2025 (USD Mn)
 

Chapter 8: Regional Market Outlook

  • Liver Cancer Molecular Diagnostics Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2014-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2014-2025
    • Canada Market Landscape Analysis-2014-2025
  • Europe Market Landscape Analysis, 2014-2025 (USD Mn)
    • UK Market Landscape Analysis, 2014-2025
    • Germany Market Landscape Analysis, 2014-2025
    • France Market Landscape Analysis, 2014-2025
    • Italy Market Landscape Analysis, 2014-2025
    • Spain Market Landscape Analysis, 2014-2025
  • Latin America Market Landscape Analysis, 2014-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2014-2025
    • Mexico Market Landscape Analysis, 2014-2025
    • Colombia Market Landscape Analysis, 2014-2025
  • Asia pacific Market Landscape Analysis, 2014-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2014-2025
    • China Market Landscape Analysis, 2014-2025
    • India Market Landscape Analysis, 2014-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South Africa Market Landscape Analysis, 2014-2025
 

Chapter 9: Pricing Analysis

 
  • Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 10: Liver Cancer Molecular Diagnostics Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 11: Liver Cancer Molecular Diagnostics Merger & Acquisition Outlook

  • Major licensing deals
  • Factors driving M&A in Liver Cancer Molecular Diagnostics market
  • Key trends and future outlook

Chapter 12: Liver Cancer Molecular Diagnostics Regulatory & Patent Outlook

  • Regulatory Landscape by Region (U.S., Europe, and RoW)
  • Patent Landscape by Region (U.S., Europe, and RoW)

Chapter 13: Competitive Landscape 

  • Cepheid
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Beckton Dickinson
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Gen Probe (Hologic)
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Qiagen
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Roche Diagnostics
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bayer Healthcare
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Abbott Laboratories
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Dako
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Danaher Corporation
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Siemens
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sysmex Corporation
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Grifols
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Biomérieux Sa
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
     

List of Tables

 
  • TABLE 1 Liver Cancer Molecular Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Liver Cancer Molecular Diagnostics Market, 2014 – 2025
  • TABLE 3 Global Liver Cancer Molecular Diagnostics Market Analysis by Product-2017
  • TABLE 4 Global Liver Cancer Molecular Diagnostics Market Analysis by Technology -2017
  • TABLE 5 Global Liver Cancer Molecular Diagnostics Market Analysis by Application-2017
  • TABLE 7 Global Liver Cancer Molecular Diagnostics Market Analysis by Geography-2017
  • TABLE 8 Global Liver Cancer Molecular Diagnostics Market Analysis by Leading Brands-2017
  • TABLE 9 Liver Cancer Molecular Diagnostics Market - Key market driver analysis
  • TABLE 10 Liver Cancer Molecular Diagnostics Market - Key market restraint analysis
  • TABLE 11 North America Market Liver Cancer Molecular Diagnostics Landscape Analysis, 2014-2025 (USD Mn)
  • TABLE 12U.S. Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 13 Canada Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 14 Europe Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025 (USD Mn)
  • TABLE 15 U.K Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 16 Germany Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 17 France Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 18 Italy Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 19 Spain Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 20 Latin America Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025 (USD Mn)
  • TABLE 21 Brazil Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 22 Mexico Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 20 Colombia Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 21 Asia pacific Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025 (USD Mn)
  • TABLE 22 Japan Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 23 China Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 24 India Liver Cancer Molecular Diagnostics Market Landscape Analysis, 2014-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
 

List of Figures

 
  • 1 Liver Cancer Molecular Diagnostics Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Liver Cancer Molecular Diagnostics Market – PESTEL Analysis
  • 7 Liver Cancer Molecular Diagnostics Market Share by Product Type, 2017 & 2025
  • 8 Liver Cancer Molecular Diagnostics Market Share by Technology Type, 2017 & 2025
  • 9 Liver Cancer Molecular Diagnostics Market Share by Application Type, 2017 & 2025
  • 10 Liver Cancer Molecular Diagnostics Market Share by Region, 2017 & 2025
 

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:      
  • The global oncology molecular diagnostics market was valued at $1.39 Billion in 2017 and is forecast to grow at a modest 12.6 % CAGR between 2018 and 2025, culminating in 2025 global sales of $4.5 Billion.
  • Global oncology molecular diagnostic market is expected to grow at a faster rate than expected due to rising demand from physicians, failure rate of conventional diagnosis, better and early detection, reducing cost of molecular diagnostic, improvement reimbursement coverage, technological, rising prevalence of chronic diseases and rapid increase in the geriatric population across the globe.
  • Reagents and kits are a large component of the overall market for Oncology Molecular Diagnostic. There are several options in the market for a wide range of usages from Thermo Fisher to Qiagen to Luminous Bioscience.
  • Major players in the market include Cepheid, Beckton Dickinson, Gen Probe (Hologic), Qiagen, Roche Diagnostics, Bayer Healthcare, Dako, Abbott Laboratories, Danaher Corporation, Siemens, Sysmex Corporation, Grifols, and Biomérieux Sa.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involve in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global liver cancer molecular diagnostics market was valued at $115.3 Million in 2017 and is forecast to grow at a modest 13.7 % CAGR between 2018 and 2025, culminating in 2025 global sales of $355.2 Million.

 

Individualized and targeted treatments are reshaping oncology. Key to personalized medicine lies in molecular pathology. Use of high throughput sequencing technologies and identification of therapeutic targets has led to the development of many molecular diagnostic tests, which are far more superior to the conventional pathology tests. Despite recent development in novel targets and potential markers, the implementation of tests to identify in clinical and pathology practice is hard to achieve.

 

Global oncology molecular diagnostic market is expected to grow at a faster rate than expected due to rising demand from physicians, failure rate of conventional diagnosis, better and early detection, reducing cost of molecular diagnostic, improvement reimbursement coverage, technological, rising prevalence of chronic diseases and rapid increase in the geriatric population across the globe. Moreover, high unmet needs across the developing and emerging nations is also expected to boost the molecular diagnostics over the next few years.

 

Liver cancer is more prevalent in countries in sub-Saharan Africa and Southeast Asia than in the US. In many of these countries it is the most common type of cancer. More than 700,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. There are various types of primary liver cancer occur in adults. Some of the most common liver cancers include Hepatocellular carcinoma, Cholangiocarcinoma (bile duct cancer), and Angiosarcoma. These are named after the cells from which they developed. Among these, 80% of adult primary liver cancers are hepatocellular carcinomas, 10% to 20% of adult primary liver cancers are cholangiocarcinomas and only 1% of adult primary liver cancers are angiosarcomas. The outlook for liver cancer is poor, as it is often diagnosed at a late stage, at which point it has already spread to other organs or other parts of the liver. The survival rate reduces as the staging gets closer to Stage IV. People diagnosed at an early stage have a 5-year survival rate of 31%.

.

 

Aging factors significantly contribute to the onset of several oncological conditions. For instance, the average age for stomach cancer diagnosis is 69 and about every 6 in 10 patients diagnosed are aged above 65. The American Cancer Society estimates that nearly 28,000 stomach cancer cases will be diagnosed in 2017, with 17,750 cases in men and 10,250 cases in women. In the UK, as per 2014 Cancer Research estimates, each year nearly 6,682 new cases are detected, and the average survival rate is 15%.

.

 

Molecular Diagnostic Market 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Endoscope Equipment”

 

Estimated Average Oncology Molecular Diagnostics product cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the molecular diagnostics products are available at USD 3600. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Product Insight

 

The oncology molecular diagnostics market is broadly segmented by product as Instruments, Reagents & Kits, Software & Services. Instruments like QIAsymphony SP/AS from QIAGEN and ELITe InGenius® from Elitech group are some of the instruments which integrate extraction, amplification and result interpretation with an unprecedented flexibility and assay menu possibility.

 

Reagents and kits are a large component of the overall market for Oncology Molecular Diagnostic. There are several options in the market for a wide range of usages from Thermo Fisher to Qiagen to Luminous Bioscience.

 

Today’s demanding business climate, rapid delivery of results from the lab directly to the patient has dramatically increased the informatics integration and workflow challenges in clinical testing and molecular diagnostic labs. Nautilus LIMS™ from Thermo Fisher is such a software solution.

 

Test Location Insights

 

Specialty clinics and laboratories constitute primary test locations for molecular diagnostic. Laboratories having high volume capacity are driving the market. However, to facilitate early diagnostic, POC (Pont of Care) diagnostic is increasing. Some of these POCs are retail clinics & pharmacies, student health clinics, neighborhood ambulatory care clinics, physician offices, CLIA waived labs, CLIA moderately complex labs, hospital floor (near-patient bedside), emergency rooms, intensive care units, rural health clinics, nursing homes, assisted living residence. CLIA waived labs are 5% of total POC and used primarily for respiratory testing.

 

Technology Insights

 

The oncology molecular diagnostics market is broadly segmented by technology as PCR, In Situ Hybridization, Chips and microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass spectrometry, Sequencing, Transcription Mediated Amplification. In 2017, PCR technology market share was little above 30% of market share. DNA and RNA sequencing expected to grow at a CAGR of 18% during the forecasted period and will provide high throughput analysis.

 

Regional Segmentation

 

North America accounted for over 46% revenue share in 2016. The key reasons attributed for the high share include the high prevalence of stomach and GI cancers, strong reimbursement framework, highly skilled medical professionals, technological advancements and government support for R&D and innovation in medical devices sector. Moreover, the presence of high-end hospital and POC and high emphasis on preventive screening is expected to boost the usage rates over the forecast period.

 

Asia Pacific is expected to register the maximum CAGR of 7.5% through 2017 to 2025. The rapid increase in a number of cancer cases, growing healthcare expenditure and skill training, and improvement in reimbursement scenario are expected to favor the high market growth in the region.

 

Merger and Acquisition Insight

 

With the rising investor confidence and positive market trends, several players are actively engaging in merger and acquisition activities. Moreover, the disruption in the global healthcare market due to political factors such as repealing Obama Care Act, changes in the regulatory framework, and other trade barriers, are anticipated to trigger merger and acquisition activities to drive market consolidation and further intensify the market competition. We have identified 4 major deals from 2014 to 2017.

 

Top Players & Company Share

 

The Oncology Molecular Diagnostic market is highly competitive and some of the key success factors include technology, pricing, and distribution channel. As of 2017, major players in the market include Cepheid, Beckton Dickinson, Gen Probe (Hologic), Qiagen, Roche Diagnostics, Bayer Healthcare, Dako, Abbott Laboratories, Danaher Corporation, Siemens, Sysmex Corporation, Grifols, and Biomérieux Sa.

 

Market Segmentation

 

Liver Cancer Molecular Diagnostics Market by Products (Revenue, USD Million, 2014 – 2025)

  • Instruments
  • Reagents & Kits
  • Software & Services

 

Liver Cancer Molecular Diagnostics Market by Test Location (Revenue, USD Million, 2014- 2025)

  • Clinics/Lab
  • Point of Care

 

Liver Cancer Molecular Diagnostics Market by Technology (Revenue, USD Million, 2014- 2025)

  • PCR
  • In Situ Hybridization
  • Chips and microarrays
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Mass spectrometry
  • Sequencing
  • Transcription Mediated Amplification

 

Liver Cancer Molecular Diagnostics Systems Regional Outlook (Revenue, USD Million, 2014- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650